{"id":3260,"date":"2018-09-28T15:03:21","date_gmt":"2018-09-28T09:33:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3260"},"modified":"2025-05-06T13:38:16","modified_gmt":"2025-05-06T08:08:16","slug":"companion-diagnostics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics","title":{"rendered":"Companion Diagnostics"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Companion diagnostics<\/strong> domain falls within the larger field of study called <strong>pharmacogenomics<\/strong>, which employs the person\u2019s genomic makeup to predict a drug response or to tailor therapy specifically for that patient. The<strong> US FDA<\/strong> depicts companion diagnostics as an <strong>in vitro diagnostic device<\/strong> or an imaging tool, which provides information essential for the safe and effective use of a corresponding therapeutic, preventive, or prophylactic product. These unprecedented diagnostic devices are the critical part of\u00a0currently targeted cancer therapy regimens and impose a very good impact on the lowering of the unnecessary morbidity and providing the better treatment access to the patients.<\/p>\n<p style=\"text-align: justify;\">For a long time, technologies such as quantitative real-time polymerase chain reaction, in situ\u00a0hybridization, and immunohistochemistry have been traditionally used for diagnosing or detecting the relevant disease biomarkers however, due to the arrival of the high throughput sensitive approaches had changed the diagnostic scenario and thereby created a shift in the enabling technology platform for Companion Diagnostics. These high throughput technologies ranged from single molecule real-time sequencing, next-generation sequencing, and quantitative histopathology to digital pathology.<\/p>\n<p style=\"text-align: justify;\">An excellent example of a companion diagnostic approval was the <strong>COBAS BRAF V600E<\/strong> test, which received simultaneous FDA marketing approval along with <strong>vemurafenib<\/strong> for metastatic melanoma patients. Other glaring example of already approved companion diagnostics kits are \u201c<strong>Exjade Ferriscan\u00a0drug-device kit<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/thalassemia-market\">Thalassemia<\/a>, Gleevec PDGFRB FISH drug-device kit for Gleevec Eligibility in Myelodysplastic Syndrome\/Myeloproliferative Disease, Myelodysplastic Syndrome\/Myeloproliferative Disease,l <strong>Herceptin<\/strong> (trastuzumab) INSITE HER\u20102\/NEU drug-device kit for Breast cancer, Keytruda PD\u2010L1 IHC 22C3 PharmDx drug-device kit for <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">Non\u2010small cell lung cancer<\/a> and Lynparza <strong>BRACAnalysis CDx\u00a0drug-device kit<\/strong> for Ovarian cancer.<\/p>\n<p style=\"text-align: justify;\">Currently, several major companies have pulled up their socks and are innovating the treatment outcomes of their respective interventions by entering in to \u201cdrug-device deals and; collaborations\u201d to better tailor the treatments with their interventions.<\/p>\n<p style=\"text-align: justify;\">Several Tier 1 companies that are evaluating their intervention in this arena are<strong> Eli Lilly<\/strong> which is evaluating Erbitux with CDx device Therascreen KRAS PCR by Qiagen for<a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\"><strong> Colorectal Cancer<\/strong><\/a>, <strong>Novartis<\/strong> which is evaluating Mekinist by the utilization of THxID\u2122 BRAF PCR Kit by bioMerieux for Melanoma treatment, <strong>Genentech<\/strong> is evaluating Tarceva and utilizing cobas EGFR mutation PCR test by <strong>Roche Diagnostics<\/strong> for Lung Cancer.<\/p>\n<p style=\"text-align: justify;\">The field is very well sprung, as so many niche companies are also joining this trend to achieve significant outcomes of their respective interventions. However, a challenge to accurate and timely diagnostics is the difficulty in obtaining tissue specimen, but as so many approvals had already been made the role of the companion diagnostic in streamlining clinical trial participant\u00a0selection had already opened the doors for further unprecedented approvals of other drug-device combos.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person\u2019s genomic makeup to predict a drug response or to tailor therapy specifically for that patient. The US FDA depicts companion diagnostics as an in vitro diagnostic device or an imaging tool, which provides information essential for the safe and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3261,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[17673,1903,1900,228,234,17674,1135,1907,292,1902,423,1899,1910,1906,1901,1904],"industry":[17226,17225],"therapeutic_areas":[17233,17228,17234],"class_list":["post-3260","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-bracanalysis-cdxa-drug-device-kit","tag-cobas-braf-v600e","tag-companion-diagnostics","tag-eli-lilly","tag-erbitux","tag-exjade-ferriscana-drug-device-kit","tag-genentech","tag-gleevec-pdgfrb-fish-drug-device-kit","tag-herceptin","tag-in-vitro-diagnostic-device","tag-novartis","tag-pharmacogenomics","tag-roche-diagnostics","tag-thalassemia","tag-us-fda","tag-vemurafenib","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Companion Diagnostics - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person\u2019s genomic makeup....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Companion Diagnostics - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person\u2019s genomic makeup....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-28T09:33:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T08:08:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"305\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Companion Diagnostics - DelveInsight Business Research","description":"Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person\u2019s genomic makeup....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics","og_locale":"en_US","og_type":"article","og_title":"Companion Diagnostics - DelveInsight Business Research","og_description":"Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person\u2019s genomic makeup....","og_url":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-28T09:33:21+00:00","article_modified_time":"2025-05-06T08:08:16+00:00","og_image":[{"width":466,"height":305,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics","url":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics","name":"Companion Diagnostics - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","datePublished":"2018-09-28T09:33:21+00:00","dateModified":"2025-05-06T08:08:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person\u2019s genomic makeup....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/companion-diagnostics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","width":466,"height":305,"caption":"Companion Diagnostics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305-300x196.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">BRACAnalysis CDx\u00c2 drug-device kit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">COBAS BRAF V600E<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Companion diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Erbitux<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Exjade Ferriscan\u00c2 drug-device kit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gleevec PDGFRB FISH drug-device kit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Herceptin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">in vitro diagnostic device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharmacogenomics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Roche Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Thalassemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">US FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">vemurafenib<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BRACAnalysis CDx\u00c2 drug-device kit<\/span>","<span class=\"advgb-post-tax-term\">COBAS BRAF V600E<\/span>","<span class=\"advgb-post-tax-term\">Companion diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Erbitux<\/span>","<span class=\"advgb-post-tax-term\">Exjade Ferriscan\u00c2 drug-device kit<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">Gleevec PDGFRB FISH drug-device kit<\/span>","<span class=\"advgb-post-tax-term\">Herceptin<\/span>","<span class=\"advgb-post-tax-term\">in vitro diagnostic device<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">pharmacogenomics<\/span>","<span class=\"advgb-post-tax-term\">Roche Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Thalassemia<\/span>","<span class=\"advgb-post-tax-term\">US FDA<\/span>","<span class=\"advgb-post-tax-term\">vemurafenib<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Sep 28, 2018","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on Sep 28, 2018 3:03 pm","modified":"Updated on May 6, 2025 1:38 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3260"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3260\/revisions"}],"predecessor-version":[{"id":31731,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3260\/revisions\/31731"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3261"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3260"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3260"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}